Torno Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Torno Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-86,500	Closed	-$2.71M	–	260
2023 Q4	$2.71M	Buy	+86,500	New	+$2.07M	0.56%	36

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Torno Capital's ACAD Position: Q1 2024 in Review

Torno Capital sold out of Acadia Pharmaceuticals (ACAD) in Q1 2024, closing a stake of 2,500 shares — an estimated $78.3K sold.

Torno Capital first reported a position in ACAD in Q4 2023 and held it in 1 quarter. The position peaked at $78.3K in Q4 2023. 267 funds tracked by Wall St. Rank hold ACAD as of Q1 2024.

Torno Capital reported no remaining Acadia Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Torno Capital sold 2,500 Acadia Pharmaceuticals shares in Q1 2024, an estimated $78.3K.
Torno Capital first reported a position in Acadia Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Torno Capital's Acadia Pharmaceuticals position peaked at $78.3K in Q4 2023.
267 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2024.

Based on Torno Capital's 13F filing for Q1 2024, filed 15 May 2024.